Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sorry guys, got to go, I have important matters to obstruct.
It's been a real pleasure.
Are you a subscriber dear?
Promise you'll never let tsafi take you to one of his airy activities or it might look like this
Sorry mn, I didn't realize it is that bad.
Torture is the old school, you can simply check their pulse,
very easy and less messy (unless of course you are a follower of the Marquis de Sade).
Is this your idea of dinner?
Not sure I want to know the answer.
Have no fear, I'll probably find you one of these days.
yes of course, but how can you tell?
Please note I used the term "can"
but how would you know?
You have never been hungry ha?
It's the Gola thing but i have a better theory (ask Fredi)
Guess he was just hypoglycemic before dinner.
You can say that again.
It's the 8th day of Sukot.
You ain't seen nothing yet.
You missed the point Dubi, I can't fly but I can fake.
Think I have a better chance with the alligator.
Sad, almost like this one
This one also deserves the title
Why Bother?
Don't know why she bothered, they seem much more interested in drinking.
This one is even worse
Personal genomics
The technology has arrived to make personal genome sequencing a reality. Companies such as 23andMe in Mountain View, California, and DNAdirect in San Francisco, either already offer personal genetic testing services or plan to in the future.
I find the "Personal Genome Project" of Harvard medical
school in Boston fascinating: they are planning to look at 1% of 100,000 genomes but rather than just look at the genomics, in which you get an idea of variation like with the HapMap, they want to actually integrate data for genomics, environment and phenotype with variation.
NIH will do 10,000 entire genomes. Then we may gain some understanding about what is going on in diseases, OR NOT.
He can't copy it as it is an MP3 file of about 2Mb.
I've downloaded it via peer2peer.
Here is the direct link (better because Yahoo links sometimes magically expire).
http://www.sec.gov/Archives/edgar/data/1006281/000089109207001770/e27195ex99_2.htm
[c/o DewDiligence]
Took me 10 sec, precisely the time needed to type what I was looking for.
Ok got the message. Thanks :)
And what did you tell him?
or better
Yes and parked nearby
No quite, more like this
You already know (and Fred too by now).
Exactly how I felt Wednesday night
I think the Gashashim used this one.
Hey Dubi can you also write Hebrew?
There is no question in my mind that genetic testing will become part of health care.
As for the ethical aspect, in this case, Perkin Elmer gets a lot of human samples, it is a commodity that has a high tag price these days. Does ViaCell have to ask permission from those donating individuals to allow a third party to use their DNA?
Citi still likes Teva, a Buy rating and $52 price target (note issued yesterday).
>The Zyprexa ruling is not as important for TEVA as for IVX<
Well that changed since...
Zyprexa Patent Upheld on Appeal - last scene
Back in Dec 2006:
Lilly’s patent covers olanzapine (Zyprexa®) and its use for the treatment of schizophrenia. Three generic manufacturers (Zenith (IVAX), Dr. Reddy’s, and Teva) filed an ANDA and Lilly responded with a complaint in the Southern District of Indiana. After a bench trial, the district court agreed with Lilly that the patent was valid, infringed, and enforceable.
The defendants appealed to the Court of Appeals of the Federal Circuit.
Yesterday the U.S. Court of Appeals ruled (as expected) that Zyprexa Patent is valid until April 2011. End of story.
LEVP looks in good spot to be the first one approved and get the Orphan Drug exclusivity for Cinryze.
Lev's Cinryze(TM) BLA Accepted for Filing by FDA
http://biz.yahoo.com/bw/071001/20071001005524.html?.v=1
Monday October 1, 7:15 am ET
Application for Acute Treatment of Hereditary Angioedema Granted Priority Review
NEW YORK--(BUSINESS WIRE)--Lev Pharmaceuticals, Inc. ("Lev" or the "Company") (OTCBB:LEVP.OB - News) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's filing of its Biologics License Application (BLA) for Cinryze(TM) (C1 inhibitor) for the acute treatment of hereditary angioedema (HAE). In addition, the FDA has designated the submission for priority review, which targets an FDA action by January 30, 2008. Lev submitted the BLA on July 31, 2007. Priority review status is granted by the FDA to products that, if approved, would be a significant improvement over existing therapies.
"We are extremely pleased that the FDA has accepted our Cinryze(TM) BLA for filing and designated it for priority review," said Joshua D. Schein, Ph.D., Chief Executive Officer of Lev. "The priority designation supports our belief in the potential of Cinryze(TM) as a replacement therapy for the treatment of HAE. There currently is no acute therapy specifically approved for the treatment of HAE, and we believe that Cinryze(TM), if approved, would represent an important option in improving the lives of patients with the disease."
The BLA submission is based on data from the Company's pivotal Phase III acute trial which met its protocol-defined, pre-specified primary endpoint with statistical significance as reported on March 14, 2007. Additional details regarding the acute study results will be presented at the 2007 Annual Meeting of the American College of Allergy, Asthma & Immunology in November.
snip
Good night young grasshopper :)
She definitely deserves a TSALASH.